ES3053508T2 - Liquid pharmaceutical composition of adalimumab - Google Patents
Liquid pharmaceutical composition of adalimumabInfo
- Publication number
- ES3053508T2 ES3053508T2 ES25179059T ES25179059T ES3053508T2 ES 3053508 T2 ES3053508 T2 ES 3053508T2 ES 25179059 T ES25179059 T ES 25179059T ES 25179059 T ES25179059 T ES 25179059T ES 3053508 T2 ES3053508 T2 ES 3053508T2
- Authority
- ES
- Spain
- Prior art keywords
- histidine
- pharmaceutical composition
- liquid pharmaceutical
- composition according
- zwitterionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. REIVINDICACIONES
1. Una composición farmacéutica líquida, que comprende adalimumab; histidina zwitteriónica; y un estabilizador de azúcar; en donde la composición está exenta de aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración colectiva de 0,1 mM como máximo;
en donde la histidina zwitteriónica está presente en una concentración entre 0,77mg/mL y 2,2 mg/mL o en una concentración entre 5 y 14 mM.
2. La composición farmacéutica líquida de acuerdo con la reivindicación 1, que comprende además un tensioactivo.
3. La composición farmacéutica líquida de acuerdo con la reivindicación 1 o la reivindicación 2, que comprende además un tonificante.
4. La composición farmacéutica líquida de acuerdo con cualquier reivindicación anterior, en donde el estabilizador de azúcar es un poliol de azúcar o un disacárido.
5. La composición farmacéutica líquida de acuerdo con la reivindicación 4, en donde el estabilizador de azúcar es trehalosa o manitol.
6. La composición farmacéutica líquida de acuerdo con la reivindicación 2, o cualquier reivindicación anterior dependiente de la misma, en donde el tensioactivo es polisorbato 80 o polisorbato 20.
7. La composición farmacéutica líquida de acuerdo con la reivindicación 3, o cualquier reivindicación anterior dependiente de la misma, en donde el tonificante no es amortiguador.
8. La composición farmacéutica líquida de acuerdo con la reivindicación 3, o cualquier reivindicación anterior dependiente de la misma, en donde el tonificante es o comprende una sal metálica.
9. La composición farmacéutica líquida de acuerdo con la reivindicación 8, en donde el tonificante es o comprende cloruro de sodio.
10. La composición farmacéutica líquida de acuerdo con cualquier reivindicación anterior, en donde la composición farmacéutica líquida comprende:
- Adalimumab;
- 5 a 14 mM de histidina zwitteriónica;
- 100 a 300 mM de un estabilizador de azúcar (por ejemplo, trehalosa);
- 10 a 200 mM un tonificante (por ejemplo, cloruro de sodio); y
Agua para inyección
- en donde la composición:
o tiene un pH entre 6,3 y 6,7 (por ejemplo, pH 6,4)
o está (sustancial o totalmente) libre de arginina; comprende arginina en una concentración de 0,1 mM como máximo;
o está (sustancial o totalmente) libre de aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración (colectiva) de 0,1 mM como máximo;
o está (sustancial o totalmente) libre de tensioactivos con la excepción opcional del polisorbato 80 o comprende uno o más de dichos tensioactivos (excluyendo opcionalmente el polisorbato 80) en una concentración (colectiva) de como máximo 1 mM; y/o
o está (sustancial o totalmente) exenta de agentes amortiguadores de fosfatos (por ejemplo, dihidrogenofosfato de sodio, hidrogenofosfato de disodio) o comprende un sistema de disolución amortiguadora de fosfatos en una concentración de 0,1 mM como máximo.
11. Un método de fabricación de una composición farmacéutica líquida, que comprende adalimumab, histidina zwitteriónica y un estabilizador de azúcar; en donde la composición no contiene aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración colectiva de como máximo 0.1 mM; y la composición comprende entre 0,77mg/mL y 2,2 mg/mL de histidina zwitteriónica o entre 5 y 14 mM de histidina zwitteriónica; en donde el método comprende: mezclar juntos, en agua, el adalimumab, la histidina zwitteriónica y el estabilizador de azúcar.
12. El método de acuerdo con la reivindicación 11, en donde el método involucra formar un sistema de disolución amortiguadora de histidina que comprenda la histidina zwitteriónica, en donde formar el sistema de disolución amortiguadora de histidina comprende mezclar la histidina zwitteriónica con clorhidrato de histidina.
13. El método de acuerdo con la reivindicación 11 o la reivindicación 12, en donde la composición farmacéutica líquida es como se reivindica en cualquiera de las reivindicaciones 1 a 10.
14. Una composición farmacéutica líquida de acuerdo con cualquiera de las reivindicaciones 1 a 10, o una
composición farmacéutica líquida obtenida por el método de acuerdo con cualquiera de las reivindicaciones 11 a 13, para su uso en el tratamiento de la artritis reumatoide, la artritis psoriásica, la espondilitis anquilosante, la enfermedad de Crohn, la colitis ulcerosa, la psoriasis crónica de moderada a grave y/o la artritis idiopática juvenil.
15. La composición farmacéutica líquida para su uso de acuerdo con la reivindicación 14, en donde el tratamiento es la artritis psoriásica, la espondilitis anquilosante, la enfermedad de Crohn, la colitis ulcerosa, la psoriasis crónica de moderada a grave y/o la artritis idiopática juvenil.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169754.0A EP2946766B1 (en) | 2014-05-23 | 2014-05-23 | Liquid pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3053508T2 true ES3053508T2 (en) | 2026-01-22 |
Family
ID=50774705
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14169754.0T Active ES2572919T3 (es) | 2014-05-23 | 2014-05-23 | Composición farmacéutica líquida |
| ES15724974.9T Active ES2683194T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES18169979T Active ES2928738T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES19215036T Active ES2955316T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida de adalimumab |
| ES25179059T Pending ES3053508T2 (en) | 2014-05-23 | 2015-05-15 | Liquid pharmaceutical composition of adalimumab |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14169754.0T Active ES2572919T3 (es) | 2014-05-23 | 2014-05-23 | Composición farmacéutica líquida |
| ES15724974.9T Active ES2683194T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES18169979T Active ES2928738T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES19215036T Active ES2955316T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida de adalimumab |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10493152B2 (es) |
| EP (6) | EP2946766B1 (es) |
| JP (3) | JP2017516847A (es) |
| CN (2) | CN108785670A (es) |
| AU (4) | AU2015263246B2 (es) |
| CA (2) | CA3050875A1 (es) |
| CY (1) | CY1120488T1 (es) |
| DE (2) | DE25179059T1 (es) |
| DK (3) | DK3148510T3 (es) |
| ES (5) | ES2572919T3 (es) |
| HK (1) | HK1257026A1 (es) |
| HR (1) | HRP20181226T1 (es) |
| HU (1) | HUE040097T2 (es) |
| IL (1) | IL249117B2 (es) |
| LT (1) | LT3148510T (es) |
| PL (1) | PL3148510T3 (es) |
| PT (1) | PT3148510T (es) |
| RS (1) | RS57772B1 (es) |
| SI (1) | SI3148510T1 (es) |
| SM (1) | SMT201800413T1 (es) |
| WO (1) | WO2015177058A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| IL277469B2 (en) | 2018-03-29 | 2024-11-01 | Airway Therapeutics Inc | Systems and methods for characterizing surfactant protein d (sp-d) oligomers |
| JP7797098B2 (ja) * | 2018-03-29 | 2026-01-13 | エアウェイ・セラピューティクス・インコーポレイテッド | サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物 |
| WO2020138517A1 (ko) * | 2018-12-24 | 2020-07-02 | 삼성바이오에피스 주식회사 | 항-TNFα 항체를 포함하는 약제학적 조성물 |
| KR20210102954A (ko) * | 2019-01-11 | 2021-08-20 | 삼성바이오에피스 주식회사 | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 |
| CN113727730A (zh) * | 2019-03-18 | 2021-11-30 | 阿尔沃科技Hf公司 | 高浓度TNFα抗体的含水制剂 |
| CN115429751B (zh) * | 2022-09-21 | 2023-11-17 | 景泽生物医药(合肥)股份有限公司 | 一种人重组卵泡刺激素注射剂及其制备方法 |
| AU2024325145A1 (en) * | 2023-08-15 | 2026-02-05 | Amgen Inc. | Acidic buffered intravenous solution stabilizers for use in methods of treatment |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6388197A (ja) * | 1986-09-30 | 1988-04-19 | Tosoh Corp | モノクロナル抗体の安定化方法 |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US5900404A (en) | 1997-08-15 | 1999-05-04 | Amgen Inc. | Chemical modification of proteins to improve biocompatibility and bioactivity |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| MX2007000891A (es) * | 2004-07-23 | 2007-04-18 | Genentech Inc | Cristalizacion de anticuerpos o fragmentos de ellos. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2569409T3 (es) | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| KR101457223B1 (ko) | 2005-06-07 | 2014-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 억제하는 안정적이고 가용성인 항체 |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| KR20110097772A (ko) | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| EP3409289B1 (en) * | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| NZ602685A (en) | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| EP2550018B1 (en) | 2010-03-22 | 2019-02-27 | F.Hoffmann-La Roche Ag | Compositions and methods useful for stabilizing protein-containing formulations |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr：fc-融合多肽组合物及使用方法 |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP2015509526A (ja) | 2012-03-07 | 2015-03-30 | カディラ ヘルスケア リミティド | 医薬製剤 |
| WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| CN104768578A (zh) | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
| WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| CN105431453A (zh) | 2012-11-01 | 2016-03-23 | 艾伯维公司 | 稳定的双重可变结构域免疫球蛋白制剂 |
| CN104707146B (zh) | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| IN2014MU00610A (es) | 2014-02-21 | 2015-09-25 | Tata Motors Ltd | |
| WO2015151115A1 (en) | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| ES2933808T3 (es) | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
| EP4119161A4 (en) | 2020-03-13 | 2024-05-15 | Samsung Bioepis Co., Ltd. | Liquid pharmaceutical composition having improved stability |
-
2014
- 2014-05-23 ES ES14169754.0T patent/ES2572919T3/es active Active
- 2014-05-23 EP EP14169754.0A patent/EP2946766B1/en not_active Not-in-force
-
2015
- 2015-05-15 AU AU2015263246A patent/AU2015263246B2/en not_active Revoked
- 2015-05-15 EP EP18169979.4A patent/EP3403646B1/en active Active
- 2015-05-15 US US15/313,480 patent/US10493152B2/en active Active
- 2015-05-15 JP JP2017513323A patent/JP2017516847A/ja not_active Withdrawn
- 2015-05-15 DE DE25179059.8T patent/DE25179059T1/de active Pending
- 2015-05-15 PL PL15724974T patent/PL3148510T3/pl unknown
- 2015-05-15 DK DK15724974.9T patent/DK3148510T3/en active
- 2015-05-15 WO PCT/EP2015/060817 patent/WO2015177058A1/en not_active Ceased
- 2015-05-15 CA CA3050875A patent/CA3050875A1/en not_active Abandoned
- 2015-05-15 RS RS20180919A patent/RS57772B1/sr unknown
- 2015-05-15 EP EP15724974.9A patent/EP3148510B1/en not_active Revoked
- 2015-05-15 DE DE23189888.3T patent/DE23189888T1/de active Pending
- 2015-05-15 PT PT157249749T patent/PT3148510T/pt unknown
- 2015-05-15 CN CN201810768437.8A patent/CN108785670A/zh active Pending
- 2015-05-15 ES ES15724974.9T patent/ES2683194T3/es active Active
- 2015-05-15 ES ES18169979T patent/ES2928738T3/es active Active
- 2015-05-15 SM SM20180413T patent/SMT201800413T1/it unknown
- 2015-05-15 EP EP25179059.8A patent/EP4585614A3/en active Pending
- 2015-05-15 ES ES19215036T patent/ES2955316T3/es active Active
- 2015-05-15 HR HRP20181226TT patent/HRP20181226T1/hr unknown
- 2015-05-15 EP EP23189888.3A patent/EP4249060A3/en active Pending
- 2015-05-15 LT LTEP15724974.9T patent/LT3148510T/lt unknown
- 2015-05-15 ES ES25179059T patent/ES3053508T2/es active Pending
- 2015-05-15 CN CN201580039868.5A patent/CN106659781A/zh active Pending
- 2015-05-15 CA CA2947487A patent/CA2947487C/en active Active
- 2015-05-15 EP EP19215036.5A patent/EP3659582B1/en active Active
- 2015-05-15 HU HUE15724974A patent/HUE040097T2/hu unknown
- 2015-05-15 SI SI201530341T patent/SI3148510T1/sl unknown
- 2015-05-15 IL IL249117A patent/IL249117B2/en unknown
-
2018
- 2018-08-06 CY CY20181100812T patent/CY1120488T1/el unknown
- 2018-08-27 AU AU2018222887A patent/AU2018222887B2/en active Active
- 2018-09-07 DK DKBA201800070U patent/DK201800070Y8/da not_active IP Right Cessation
- 2018-09-07 DK DKBA201800071U patent/DK201800071Y4/da not_active IP Right Cessation
- 2018-12-17 HK HK18116149.6A patent/HK1257026A1/zh unknown
-
2019
- 2019-10-10 JP JP2019187090A patent/JP6962984B2/ja active Active
- 2019-11-25 US US16/694,627 patent/US10772961B2/en active Active
-
2020
- 2020-02-14 AU AU2020201090A patent/AU2020201090B2/en active Active
- 2020-08-11 US US16/990,954 patent/US11752208B2/en active Active
-
2021
- 2021-10-12 JP JP2021167297A patent/JP2022003091A/ja active Pending
-
2022
- 2022-06-03 AU AU2022203863A patent/AU2022203863A1/en not_active Abandoned
- 2022-11-02 US US17/979,272 patent/US11752209B2/en active Active
- 2022-11-02 US US17/979,309 patent/US12109267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3053508T2 (en) | Liquid pharmaceutical composition of adalimumab | |
| NZ725360A (en) | Liquid pharmaceutical composition | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| PE20230169A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
| HRP20241660T1 (hr) | Formulacija protutijela anti-cgrp | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| HRP20191843T1 (hr) | Mikobakterijski antigenski pripravak | |
| PE20130578A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| HRP20191966T4 (hr) | Stabilizirani neproteinski klostridijalni pripravci toksina | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| HRP20161753T1 (hr) | Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| AR087305A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| JP2017516847A5 (es) |